Increased cortisol levels in hair of recent Ecstasy/MDMA users

European Neuropsychopharmacology

Volumn 24, Issue 3, 2014, Pages 369-374

  Parrott, A C ^a,c   Sands, H R ^a   Jones, L ^a   Clow, A ^b   Evans, P ^b   Downey, L A ^a,c   Stalder, T ^d  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF WESTMINSTER   (United Kingdom)

^c SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Cortisol; Ecstasy; HPA axis; MDMA; Neurohormone; Stress

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; HYDROCORTISONE; PSYCHEDELIC AGENT; STREET DRUG;

ADDICTION; CHEMISTRY; FEMALE; HAIR; HUMAN; IMMUNOASSAY; LUMINESCENCE; MALE; METABOLISM; QUESTIONNAIRE; TIME; YOUNG ADULT;

FEMALE; HAIR; HALLUCINOGENS; HUMANS; HYDROCORTISONE; IMMUNOASSAY; LUMINESCENT MEASUREMENTS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; QUESTIONNAIRES; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; YOUNG ADULT;

EID: 84894353446     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.11.006     Document Type: Article

References (49)

1. Bedi G., Redman J. Recreational ecstasy use: acute effects potentiated by ambient conditions?. Neuropsychobiology 2006, 53:113.
2. Brière F.N., Fallu J.S., Janosz M., Pagani L.S. Prospective associations between meth/amphetamine (speed) and MDMA (ecstasy) use and depressive symptoms in secondary school students. J. Epidemiol. Community Health 2012, 66:990-994.
3. Broderick J.E., Arnold D., Kudielka B.M., Kirschbaum C. Salivary cortisol sampling compliance: comparison of patients and healthy volunteers. Psychoneuroendocrinology 2004, 29:636-650.
4. Dumont G.J., Verkes R.J. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J. Psychopharmacol. 2006, 20:176-187.
5. Evans P.D., Hucklebridge F., Loveday C., Clow A. The cortisol awakening response is related to executive function in older age. Int. J. Psychophysiol. 2012, 84:201-204.
6. Farré M., de la Torre R., Mathúna B.O., Roset P.N., Peiró A.M., Torrens M., Ortuño J., Pujadas M., Camí J. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology 2004, 173:364-375.
7. Fox H.C., McLean A., Turner J.J.D., Parrott A.C., Rogers R., Sahakian B.J. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA (ecstasy) polydrug users. Psychopharmacology 2002, 162:203-214.
8. Gerra G., Zaimovic A., Ferri M., Zambelli U., Timpano M., Neri E., Marzocchi G.F., Delsignore R., Brambilla F. Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol. Psychiatry 2000, 47:127-136.
9. Gerra G., Bassignana S., Zaimovic A., Moi G., Bussandri M., Caccavari C., Brambilla F. Hypothalamic-pituitary-adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine ('ecstasy') use history: correlation with dopamine receptor sensitivity. Psychiatry Res. 2003, 120:115-124.
10. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 2003, 55:463-508.
11. Halberg F. Circadian (about twenty-four-hour) rhythms in experimental medicine. Proc. R. Soc. Med. 1963, 56:253-257.
12. Harris D.S., Baggott M., Mendelson J.H., Mendelson J.E., Jones R.T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2002, 162:396-405.
13. Hellhammer J., Fries E., Schweisthal O.W., Schlotz W., Stone A.A., Hagemann D. Several daily measurements are necessary to reliably assess the cortisol rise after awakening: state- and trait components. Psychoneuroendocrinology 2007, 32:80-86.
14. Herbert J., Goodyer I.M., Grossman A.B., Hastings M.H., de Kloet E.R., Lightman S.L., Lupien S.J., Roozendaal B., Seckl J.R. Do corticosteroids damage the brain?. J. Neuroendocrinol. 2007, 18:393-411.
15. Kirkpatrick M.G., Gunderson E.W., Perez A.Y., Haney M., Foltin R.W., Hart C.L. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2012, 219:109-122.
16. Kirschbaum C., Tietze A., Skoluda N., Dettenborn L. Hair as a retrospective calendar of cortisol production - increased cortisol incorporation into hair in the third trimester of pregnancy. Psychoneuroendocrinology 2009, 34:32-37.
17. Laws K.R., Kokkalis J. Ecstasy (MDMA) and memory function: a meta-analytic update. Hum. Psychopharmacol. 2007, 22:381-388.
18. Lovallo W.R. Stress and Health: Biological and Psychological Interactions 1997, Sage, California.
19. Manenschijn L., Koper J.W., Lamberts S.W.J., van Rossum E.F.C. Evaluation of a method to measure long term cortisol levels. Steroids 2011, 76:1032-1036.
20. Mas M., Farre M., de la Torre R., Roset P.N., Ortuno J., Segura J., Cami J. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J. Pharmacol. Exp. Ther. 1999, 290:136-145.
21. McCann U.D., Szabo Z., Vranesic M., Palermo M., Mathews W.B., Ravert H.T., Dannals R.F., Ricaurte G.A. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology 2008, 200:439-450.
22. Montgomery C., Hatton N.P., Fisk J.E., Ogden R.S., Jansari A. Assessing the functional significance of ecstasy-related memory deficits using a virtual reality paradigm. Hum. Psychopharmacol. 2010, 25:318-325.
23. Pacifici R., Zuccaro P., Farre M., Pichini S., Di Carlo S., Roset P.N., Ortuno J., Pujadas M., Bacosi A., Menoyo E., Segura J., de la Torre R. Effects of repeated doses of MDMA ("ecstasy") on cell-mediated immune response in humans. Life Sci. 2001, 69:2931-2941.
24. Parrott A.C. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav. 2002, 71:837-844.
25. Parrott A.C. Is Ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, dosage levels, and the changing perceptions of purity. Psychopharmacology 2004, 173:234-241.
26. Parrott A.C. MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 2004, 50:329-335.
27. Parrott A.C. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bio-energetic stress. J. Psychopharmacol. 2006, 20:147-163.
28. Parrott A.C. Cortisol and MDMA: neurohormonal aspects of bioenergetic stress in Ecstasy users. Neuropsychobiology 2009, 60:148-158.
29. Parrott A.C. MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans - no need for translation. Br. J. Pharmacol. 2012, 166:1518-1520.
30. Parrott A.C. MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans. Drug Alcohol Depend. 2012, 121:1-9.
31. Parrott A.C. Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research. Hum. Psychopharmacol. 2013, 28:289-307.
32. Parrott A.C. MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational 'Ecstasy' users. Neurosci. Biobehav. Rev. 2013, 37:1466-1484.
33. Parrott A.C., Milani R., Parmar R., Turner J.J.D. Ecstasy polydrug users and other recreational drug users in Britain and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 2001, 159:77-82.
34. Parrott A.C., Adnum L., Evans A., Kissling C., Thome J. Heavy Ecstasy/MDMA use at cool house parties: substantial cortisol release and increased body temperature. J. Psychopharmacol. 2007, 21:a35.
35. Parrott A.C., Lock J., Conner A.C., Kissling C., Thome J. Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology 2008, 198.
36. Parrott A.C., Gibbs A., Scholey A.B., King R., Owens K., Swann P., Ogden E., Stough C. MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study. Psychopharmacology 2011, 215:527-536.
37. Parrott, A.C., Rodgers, J., Buchanan, T., Ling, J., Heffernan, T., Scholey, A.B., 2006. Dancing hot on Ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems reported by recreational MDMA users. Human Psychopharmacology 21, 285-298.
38. Schifano F. Potential human neurotoxicity of MDMA ('Ecstasy'): subjective self-reports, evidence form an Italian drug addiction centre and clinical case studies. Neuropsychobiology 2000, 42:25-33.
39. Scholey A.B., Owen L., Gates J., Rodgers J., Buchanan T., Ling J., Heffernan T., Swan P., Stough C., Parrott A.C. Hair MDMA samples are consistent with reported Ecstasy use: findings from an internet study investigating effects of Ecstasy on mood and memory. Neuropsychobiology 2011, 63:15-21.
40. Selye H. The Stress of Life 1956, McGraw Hill, New York.
41. Stalder T., Kirschbaum C. Analysis of cortisol in hair - state of the art and future directions. Brain Behav. Immun. 2012, 26:1019-1029.
42. Stalder T., Steudte S., Alexander N., Miller R., Dettenborn L., Kirschbaum C. Cortisol in hair, body mass index and stress-related measures. Biol. Psychol. 2012, 90:218-223.
43. Stalder T., Steudte S., Miller R., Skoluda N., Dettenborn L., Kirschbaum C. Intraindividual stability in hair cortisol concentrations. Psychoneuroendocrinology 2012, 37:602-610.
44. Thomson S., Koren G., Fraser L.A., Rieder M., Friedman T.C., Van Uum S.H. Hair analysis provides a historical record of cortisol levels in Cushing's syndrome. Exp. Clin. Endocrinol. Diabetes 2010, 118:133-138.
45. Verkes R.J., Gigsman H.J., Pieters M.S.M., Schoemaker R.C., de Visser S., Kuijpers M. Cognitive performance and serotonergic function in users of Ecstasy. Psychopharmacology 2001, 53:196-202.
46. Wennig R. Potential problems with the interpretation of hair analysis results. Forensic Sci. Int. 2000, 107:5-12.
47. Wetherell M.A., Atherton K., Grainger J., Brosnan R., Scholey A.B. The effects of multitasking on psychological stress reactivity in recreational users of cannabis and MDMA. Hum. Psychopharmacol. 2012, 27:167-176.
48. Winstock A.R., Griffiths P., Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend. 2001, 64:9-17.
49. Zakzanis K.K., Campbell Z. Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up. Neurology 2006, 66:740-741.